Replies to post #189190 on Biotech Values

[DewDiligence]

CNAT +46% PM on biomarker results in NAFLD/NASH. The biomarker data are as good as can be expected, but they are not actual signs of efficacy.

There will be three other phase-2 Emricasan trials reading out in 2015 in various indications.